Áttétes emlőrák: vizsgálatok itt: Németország
52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleLong-term follow-up of patients treated with GD2IL18CART
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 20
- Run by
- Universitaet Muenster
See details and how to join2025-521497-34-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Berlin, Dresden, Duesseldorf, Erlangen, Frankfurt am Main, Frankfurt Am Main, Heidelberg, Muenster, Munich, Torgau, Ulm, Witten, Worms, Wuppertal
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 1. fázisTaking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Essen
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - No phaseTaking peoplePROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- Where
- Amberg, Ansbach, Apolda, Aschaffenburg, Augsburg, Baden-Baden, Bad Reichenhall, Balingen, Bamberg, Berlin, Bielefeld, Bonn, Brandenburg an der Havel, Braunschweig, Bremen, Bremerhaven, Coburg, Dessau, Donauwörth, Dortmund, Dresden, Düsseldorf, Eggenfelden, Erfurt, Essen, Filderstadt - Bonlanden, Frankfurt, Freudenstadt, Fürstenfeldbruck, Fürstenwalde, Gerlingen, Giessen, Halle, Hamburg, Hanover, Hansestadt Salzwedel, Heidenheim, Heilbronn, Hildesheim, Homburg/Saar, Jena, Kaiserslautern, Karlsruhe, Kassel, Kempten, Kiel, Krefeld, Kulmbach, Landshut, Leer, Leipzig, Loerrach, Lübeck, Lüneburg, Magdeburg, Mainz, Marburg, Memmingen, Mönchengladbach, Mühlhausen, München, Mutlangen, Neumarkt, Neuruppin, Neustadt am Rübenberge, Nordhausen, Nuremberg, Oldenburg, Oranienburg, Potsdam, Recklinghausen, Regensburg, Rosenheim, Rotenburg (Wümme), Saalfeld, Saarbrücken, Schwäbisch Hall, Siegen, Singen, Solingen, Stade, Stuttgart, Torgau, Troisdorf, Ulm, Walsrode, Weiden, Weinheim, Wessenfels, Westerstede, Wiesbaden, Winnenden, Witten, Wolfsburg, Wuppertal, Würzburg, Zittau
- Életkor
- 18 év to 130 év
- People
- 800
- Run by
- AstraZeneca
See details and how to joinNCT05573893 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Berlin, Wuppertal
- Életkor
- 18 év and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - 1. fázisNot yet taking people in NémetországA First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
- Where
- Essen, Magdeburg
- Életkor
- 18 év and over
- People
- 30 worldwide
- Run by
- Affibody AB
See details and how to join2024-518360-13-00 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Freiburg im Breisgau, Heidelberg, Ulm
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisTaking peopleA clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
- Where
- Cologne, Duesseldorf, Essen, Frankfurt am Main, Hamburg, Hildesheim, Moenchengladbach, Muenster, Munich, Schwerte, Ulm, Witten
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- WSG Women's Cancer Study Group GmbH
See details and how to join2024-511392-15-00 - 3. fázisNot yet taking people in NémetországElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Aschaffenburg, Augsburg, Berlin, Dessau-Rosslau, Duesseldorf, Essen, Georgsmarienhuette, Heidelberg, Moenchengladbach, Worms
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseBefejeződöttAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Essen, München
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - 3. fázisTaking peoplePhase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Where
- Cologne, Essen, Frankfurt, Hamburg, Hildesheim, Mönchengladbach, München, Münster, Schwerte, Ulm
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Women's Cancer Study Group GmbH
See details and how to joinNCT07281833 - 2. fázisTaking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Aschaffenburg, Augsburg, Dresden, Essen, Potsdam, Worms
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - 1. fázisNot yet taking people in NémetországFirst-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer
- Where
- Aachen, Duesseldorf
- Életkor
- 18 év and over
- People
- 18
- Run by
- Universitaetsklinikum Aachen AöR
See details and how to join2025-524027-49-00 - 1/2. fázisTaking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Erlangen
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - No phaseTaking peopleElacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
- Where
- Freiburg im Breisgau, Paderborn, Ravensburg
- Életkor
- 18 év and over
- People
- 500
- Run by
- iOMEDICO AG
See details and how to joinNCT07563595 - 2. fázisNot yet taking people in NémetországA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Velbert
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - 2. fázisTaking peopleDiscontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life
- Where
- Berlin, Bremen, Dresden, Georgsmarienhuette, Gerlingen, Hamburg, Leer (ostfriesland), Mainz, Muelheim an der Ruhr, Oberhausen, Ravensburg, Regensburg, Singen (hohentwiel), Soest-Paradiese, Velbert
- Életkor
- 18 év and over
- People
- 120
- Run by
- Institut fuer Klinische Krebsforschung IKF GmbH
See details and how to join2023-504141-31-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
- Életkor
- 18 év and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - 1/2. fázisTaking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Essen, Jena
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 - 2. fázisTaking peopleInvestigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
- Where
- Berlin, Bielefeld, Bonn, Eschweiler, Essen, Frankfurt Am Main, Georgsmarienhuette, Goslar, Munich, Troisdorf, Tuebingen, Witten
- Életkor
- 18 év to 64 év
- People
- 140 worldwide
- Run by
- Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00 - 1. fázisTaking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Cologne, Essen, Munich, Rostock
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - 2. fázisTaking peopleTrastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
- Where
- Berlin, Bottrop, Duesseldorf, Eschweiler, Essen, Frankfurt Am Main, Muenster, Munich, Oldenburg, Potsdam, Regensburg, Schwerte, Witten, Wuppertal
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- SOLTI Breast Cancer Research Group
See details and how to joinNCT07371585 · EU 2025-521805-41-00 - 3. fázisTaking peopleFDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
- Where
- Essen, Muenster, Munich
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT06877949 · EU 2023-508591-11-00 - No phaseTaking peoplePraegnant Breast Cancer: Early/Advanced/Metastatic
- Where
- Aachen, Amberg, Ansbach, Augsburg, Bamberg, Bayreuth, Berlin, Böblingen, Bonn, Bottrop, Chemnitz, Darmstadt, Deggendorf, Donauwörth, Dresden, Düsseldorf, Eggenfelden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Fürstenwalde, Fürth, Georgsmarienhütte, Halle, Hamburg, Heidelberg, Herne, Hösbach, Kaiserslautern, Karlsruhe, Kassel, Kiel, Koblenz, Langen, Leer, Leipzig, Lübeck, Mannheim, Mayen, München, Neuruppin, Nürtingen, Ostfildern, Paderborn, Recklinghausen, Regensburg, Rüdersdorf, Stralsund, Torgau, Tübingen, Ulm, Wetzlar, Würselen, Würzburg
- Életkor
- 18 év to 99 év
- People
- 13 500
- Run by
- University Hospital Tuebingen
See details and how to joinNCT02338167 - No phaseTaking peopleCATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
- Where
- Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg, Stuttgart, Tübingen, Ulm, Würzburg
- Életkor
- 14 év to 100 év
- People
- 5000
- Run by
- German Cancer Research Center
See details and how to joinNCT05652569